semaglutide fda approval mash WEGOVY GETS APPROVAL: The weight-loss drug Wegovy just got to treat a common and serious liver condition known as (Metabolic Dysfunction-Associated Steatohepatitis), adding to a long list of benefits GI and Hepatology News -

At physiological pH, cytochrome c has a net positive charge (+8), establishing an electrostatic bond with the anionic cardiolipin (Gonzalvez and Gottlieb, 2007)

An exploratory DEXA substudy of the STEP 1 trial (140 participants, 68 weeks) found that semaglutide 2.4 mg produced a 19.3% reduction in total fat mass and a 9.7% reduction in total lean body mass with the proportion of lean mass relative to total body mass actually increasing by 3.0 percentage points because fat was lost more rapidly. These results were exploratory and not corrected for statistical multiplicity, so they should be interpreted accordingly

It was easy to use and store

Western blotting For total lysate preparation, T-cells (1 10 6 T-cells/ml) were washed with PBS and lysed using PBS with 1x reducing or non-reducing sample buffer